Key result
Higher circulating CILP-1 levels independently predicted a higher risk of 1-year all-cause mortality in patients with chronic heart failure, with a hazard ratio of 1.52 per 1-SD increase.
Why the study?
Although CILP-1 is associated with myocardial remodelling, its prognostic value in patients with heart failure remained to be elucidated.
Does elevated circulating CILP-1 predict 1-year all-cause mortality in patients with chronic heart failure and LVEF <50%?
Cohort (n=210)
No
Does elevated circulating CILP-1 predict 1-year all-cause mortality in patients with chronic heart failure and LVEF <50%?
Circulating CILP-1 is a novel independent prognostic biomarker that predicts 1-year all-cause mortality in patients with chronic heart failure and LVEF <50%.
May refine mortality risk stratification in chronic HF with LVEF<50%; leaves open validation and incremental utility.
AIMS: Emerging evidence suggests that cartilage intermediate layer protein 1 (CILP-1) is associated with myocardial remodelling. However, the prognostic value of circulating CILP-1 in patients with heart failure (HF) remains to be elucidated. This study aimed to investigate whether circulating CILP-1 can independently predict the outcome of chronic HF. METHODS AND RESULTS: This prospective cohort study included 210 patients with chronic HF and left ventricular ejection fraction <50% between September 2018 and December 2019. The primary endpoint was 1 year all-cause mortality. During the 1 year follow-up, 28 patients died. In multivariable Cox proportional hazards regression analysis, higher CILP-1 levels were independently associated with a higher risk of mortality after adjusting for potential confounding factors. In Kaplan-Meier analysis, patients with CILP-1 levels above the median had a significantly higher mortality rate than those with CILP-1 levels below the median (log-rank P = 0.015). In addition, CILP-1 significantly improved prognostic prediction over N-terminal pro-brain natriuretic peptide by an increase in net reclassification improvement (P = 0.043) and a trend towards an increase in integrated discrimination improvement (P = 0.118). CONCLUSIONS: Circulating CILP-1 is a novel independent prognostic predictor in chronic HF.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) conducted a cohort in Chronic heart failure (n=210). Circulating CILP-1 levels vs. Lower CILP-1 levels was evaluated on 1 year all-cause mortality (HR 1.52, 95% CI 1.11-2.08, p=0.009). Higher circulating CILP-1 levels independently predicted a higher risk of 1-year all-cause mortality in patients with chronic heart failure, with a hazard ratio of 1.52 per 1-SD increase.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: